Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

et of estimated distributor discounts, government-mandated discounts and rebates, and estimated product returns.  Any future revenues are dependent on market acceptance of PIXUVRI, the reimbursement decisions made by governmental authorities in each country where PIXUVRI is available for sale and other factors. 

Loss from operations for the second quarter of 2013 was $17.9 million, compared to $49.4 million for the same period in 2012.  For the first six months of 2013, loss from operations was $36.3 million compared to $67.5 million for the same period in 2012. The amount recorded for the three and six months ended June 30, 2012 included a $29.1 million expense for acquired in-process research and development related to the acquisition of pacritinib from S*BIO Pte Ltd.  Non-cash, share-based compensation expense for the second quarter and first six months of 2013 was $2.0 million and $4.4 million, respectively, compared to $3.1 million and $5.1 million for the same periods in 2012.

The net loss for the second quarter of 2013 was $18.0 million, or ($0.17) per share, compared to $58.6 million, or ($1.38) per share, for the same period in 2012. For the first six months of 2013, net loss was $37.4 million, or ($0.35) per share, compared to $76.0 million, or ($1.83), per share for the same period in 2012.

As of June 30, 2013, CTI's cash and cash equivalents totaled $28.6 million.

Financial Guidance for 2013CTI reaffirms prior financial guidance that, for 2013, loss from operations excluding non-cash, share-based compensation expense, which is a non-GAAP measure, is expected to be approximately $60 to $65 million.  Year-to-date for the six month period ended June 30, 2013, loss from operations, excluding non-cash share-based compensation expense, which is a non-GAAP measure, was $31.9 million.  For more information regarding CTI's use of these non-GAAP measures and a reconciliation of non-GAAP los
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 The CAQH® Universal Provider Datasource® (UPD®) ... as the go-to resource for complete and reliable ...  Three out of five licensed and practicing physicians ... service. About 7,000 additional providers are registering each ...
... 2011 Instrumentation Laboratory (IL) today announced the appointment ... effective May 1, 2011.  Mr. Benet began his career ... Vice President of Worldwide Marketing, Sales and Service.   ... Josep Manent who served as CEO since 1999.  Under ...
Cached Medicine Technology:900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 2900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 3Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer 2
(Date:12/24/2014)... 2014 For nearly 20 years, June ... babies, graces, and all of life's rites of passage. ... Nancy Tupper Ling, in Toasts: The Perfect Words ... , Organized by category and containing many original ... anywhere else, this timely tome contains sayings famous and ...
(Date:12/24/2014)... December 24, 2014 Attorneys handling talcum ... an update to their website, the Talcum Powder ... between talcum powder class action lawsuits and ovarian cancer ... and ovarian cancer updates at their website, which serves ... for ovarian cancer claims are not the same as ...
(Date:12/24/2014)... Dr. Ronald Receveur, a New Albany ... dental implants in a day, has written a ... teeth-whitening treatments. , In his blog published Dec. ... writes that overusing teeth-whitening treatments can lead to tooth ... , “Because teeth-whitening treatments are available in ...
(Date:12/24/2014)... Thompson HealthDay Reporter TUESDAY, ... the experimental Ebola vaccine that U.S. officials are preparing to ... precursor of that vaccine produced a safe and potent immune ... when given to more than 100 Ugandans in 2009 and ... that could potentially protect a person against infection by Ebola, ...
(Date:12/24/2014)... -- Long-term fear of terrorists may damage your heart and ... from Israel suggests. , , Conducted by researchers from the ... Israel, the threat of war and terrorism has been a ... wanted to test whether fear of terrorism can predict an ... author Hermona Soreq, a professor of molecular neuroscience, said in ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Terrorism Fears May Shorten Your Life, Study Finds 2
... make the best use of the impasse in the US over ... global //hub in that sphere, scientist and entrepreneur Dr William J ... Corp, a leading biopharma and vaccine company in the US, was ... is participating in the BioAsia 2004 summit being held there. ...
... are in terminal decline because of global warming, scientists have ... year revealed that the rate of melting across the world ... glaciers in jeopardy. ,The loss of glaciers ... of millions of people within a few decades, experts warned. ...
... A new study reports that recent decline in breast cancer ... receptor (ER)-positive tumors and women younger than 70//. ... April 2 in the Journal of Clinical Oncology (JCO). ... average age of breast cancer diagnosis is 62. ...
... she wrote it off as just a part of growing ... month// .” ,“I was increasingly having painful menstrual ... 43. ,After running some tests, her doctor discovered ... in 10 women, usually of childbearing age. In addition to ...
... being led to believe that, if they get circumcised, ... a ‘vaccine;’ but it is not a vaccine// and ... false pretenses. ,“The century-old circumcision ‘experiment’ in ... Africa be any different?” asks Dan Bollinger, director of ...
... Prime Minister Girija Prasad Koirala who, despite his indifferent health ... coming to the SAARC summit. ,Addressing the opening ... statesman of Nepal, also used the occasion to confess to ... gambled 60 years of my political career to have a ...
Cached Medicine News:Health News:India Should Take the Lead in Stem Cell Research, Expert 2Health News:Bolivian Glacier Melts, Dangerously Fast 2Health News:Breast Cancer? ER Positive or Negative 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 2Health News:Hope for Ending the Pain, Infertility of Endometriosis? 3Health News:Promoting Circumcision to Prevent HIV is Misguided and Will Backfire: ICGI 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: